DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

AstraZeneca Pharma India Limited — Credit Rating- New

NSE 1 hr ago·16 Oct 2026, 9:31 am

AstraZeneca Pharma India

AstraZeneca Pharma India has informed stock exchanges about a new credit rating for the company. This rating is an independent assessment of the firm's ability to meet its financial obligations and manage risk.

For investors, this development is primarily a transparency update. A new rating can signal changes in the company's financial health or creditworthiness, which may influence how lenders and the market view the firm's stability over time.

Investors should monitor the specific details of this new rating. A change in the rating outlook or a shift in the assigned grade can offer clues about the company's financial strategy and future borrowing costs.